Rasagiline: an anti-Parkinson drug with neuroprotective activity

Reference

• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study. Arch. Neural. 59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Sagi I, Huberman M eta/and the Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Gun. Neuropharmacol 23(6), 324–330 (2000).
   Google Scholar
• Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargy1-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. Pharmacol 132(2), 500–506 (2001).
   Google Scholar
• Kalir A, Sabbagh A, Youdim MBH. Selective suicide acetylenic and reversible inhibitors of monoamine oxidase A and B. Br. Pharmacol 73, 55–64 (1981).
   Google Scholar
• Finberg JP, Youdim MB. Pharmacological properties of the antiParkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43 (7), 1110–1118 (2002).
   PubMed Web of Science ®Google Scholar
• Finberg JP, Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. BE J Pharmacol. 77(1), 13–21 (1982).
   Google Scholar
• Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. BE J Pharmacol. 73(1), 65–74 (1981).
   Google Scholar
• Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Brj Pharmacol. 85(2), 541–546 (1985).
   Google Scholar
• Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. PTchopharmacol. 5, 393–408 (1972).
   PubMedGoogle Scholar
• Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225(235), 817–820 (1970).
   PubMedGoogle Scholar
• Youdim MB, Collins GG, Sandler M, Bevan Jones AB, Pare CM, Nicholson WJ. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 236(5344), 225–228 (1972).
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Riederer P, Youdim MB, Linauer W The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. j Neural. Transm. 36(3-4), 303–326 (1975).
   Google Scholar
• Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with `Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1 (8009), 439–443 (1977).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Shaw KM, Kohout L etal. Deprenyl in Parkinson's disease. Lancet 2(8042), 791–795 (1977).
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Knoll J, Riederer P, Youdim MB, Ham V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J. Neural. Transm. 64(2), 113–127 (1985).
   Google Scholar
• Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl. J. Med. 309(5), 310 (1983).
   Google Scholar
• Bums RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 80(14), 4546–4550 (1983).
   Google Scholar
• Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea-pig and monkey. Bychopharmacol. Bull. 20(3), 548–553 (1984).
   Google Scholar
• Chiueh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in the rat. Eur Pharmacol. 100(2), 189–194 (1984).
   Google Scholar
• Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120(2), 574–578 (1984).
   Google Scholar
• Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim M. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17 (10), 729–762 (2003).
   PubMed Web of Science ®Google Scholar
• Palm S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neural. 32(6), 804–812 (1992).
   Google Scholar
• Riederer P, Sofic E, Rausch WD et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (2), 515–520 (1989).
   PubMed Web of Science ®Google Scholar
• Dexter DT, Wells FR, Lees AJ eta]. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J: Neurochem. 52(6), 1830–1836 (1989).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancetl (8649), 1269 (1989).
   Google Scholar
• Janetzky B, Hauck S, Youdim MB et al Unaltered aconitase activity but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169 (1-2), 126–128 (1994).
   PubMed Web of Science ®Google Scholar
• Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180), 345–348 (1988).
   PubMed Web of Science ®Google Scholar
• Double KL, Gerlach M, Schunemann V et al Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66(3), 489–494 (2003).
   PubMed Web of Science ®Google Scholar
• Grunblatt E, Mandel S, Maor G, Youdim MBH. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. I Neurochem. 78, 1–12 (2001).
   PubMed Web of Science ®Google Scholar
• Mandel M, Weinreb 0, Youdim MBH. Using cDNA to assess Parkinson's disease models and the effects of neuroprotective drugs. TIP524, 184–191 (2003).
   Google Scholar
• Glinka Y, Youdim MBH. Inhibition of mitochondrial complex I and IV by 6-hydroxydopamine. Eur j Pharamcol 292, 329–332 (1995).
   PubMed Web of Science ®Google Scholar
• Glinka Y, Tipton KF, Youdim MBH. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. j Neurochem. 66, 2004–2010 (1996).
   Google Scholar
• Orth M, Schapira AH. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40(6), 533–541 (2002).
   PubMed Web of Science ®Google Scholar
• Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural. 7iansm. 110(5), 509–515 (2003).
   Google Scholar
• Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargy1-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mal Neurobial 21(6), 555–573 (2001).
   Google Scholar
• Youdim MBH, Wadia A, Tatton NA, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in viva Ann NY Acad. Sri. 939,450–458 (2001).
   Google Scholar
• Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R) and (S)-aminoindan, rasagiline and TV1022. J. Neural. 7iansm. 60, S171—S186 (2000).
   Google Scholar
• Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neumtoxical TiTatol. 24(5), 675–682 (2002).
   Google Scholar
• Maruyama W Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109(4), 467–481 (2002).
   Google Scholar
• Naoi M, Maruyama W, Akao Y, Yi H Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R) salsolinol and neuroprotection by propargylamines. Neural. Transm. 109(5-6), 607–621 (2002).
   PubMed Web of Science ®Google Scholar
• Hunot S, Brugg B, Ricard D et al Nuclear translocation of NF-KB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl Acad. Sci USA 94(14), 7531–7536 (1997).42 Youdim MB, Grunblatt E, Mandel S. The pivotal role of iron in NF-K B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann NY Acad. Sci. 890, 7–25 (1999).
   Google Scholar
• Yogev-Falach M, Amit T, Bar-Am 0, Youdim MBH. the importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in mapk-dependent amyloid precursor protein processing. FASEB (2003) (In Press).
   Google Scholar
• Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bc1-2 overexpression and an antiParkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R) salsolinol. Neurochem. 78(4), 727–735 (2001).
   Google Scholar
• Akao Y, Maruyama W, Shimizu S eta! Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R) salsolinol, an endogenous neurotoxin and is inhibited by Bc1-2 and rasagiline, N-propargy1-1(R)-aminoindan. Neurachem. 82(4), 913–923 (2002).
   Google Scholar
• Akao Y, Maruyama W, Yi H, Shamoto- Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargy1-1(R)-aminoindan (rasagiline), enhances expression of antiapoptotic bc1-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326(2), 105–108 (2002).
   Google Scholar
• Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neurone degeneration mutants. j Neumsci. Res. 38,64-74 (1994).
   Google Scholar
• Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol anti-oxidative therapy of Parkinsonism. Ann Neural. 44, S160—S166 (1988).
   Google Scholar
• Bar Am 0, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selgiline. Neurosci. Lett. (2003) (In Press).
   Google Scholar
• Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovich. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischaemia in PC-12 cells. Eur. I Pharmacol 434(3), 109–116 (2002).
   Google Scholar
• Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC-12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58(3), 456–463 (1999).
   Google Scholar
• Glezer S, Finberg JP. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur. Pharmacol 472(3), 173–177 (2003).
   Google Scholar
• Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargy1-1R-aminoindan). Adv. Neural 80,495–499 (1999).
   Google Scholar
• Lees AJ. Comparison oftherapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's disease Research Group of the United Kingdom. BE Merl 311, 1602–1167 (1995).
   Google Scholar
• Ben Sholomo Y, Churchyard A, Heal J, Overstall P, Ockelford J, Lees Al. Investigation by the Parkinson's disease Research group of the United Kingdom into excess mortaility seen with combined levodopa and selegiline treatment of patients with early and mild Parkinson's disease: further results of randomized trail and confidential inquiry. BE Merl 1316, 1191–1196 (1998).
   Google Scholar
• Gassen M, Lamensdorf I, Armony T, Finberg JP, Youdim MB. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J. Neural Transm. 110, 171–182 (2003).
   Google Scholar
• Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischaemia in the rat. J. Neural. 7iansm. 106(7–8), 593–606 (1999).
   Google Scholar
• Pellegrini-Giampietro DE, Peruginelli F, Meli E eta! Protection with metabotropic
   Google Scholar
• Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eurj Pharmacol 366(2-3), 127–135 (1999).
   PubMed Web of Science ®Google Scholar
• Speiser Z, Katzir 0, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem. Behar/. 60(2), 387–393 (1998).
   Google Scholar
• Speiser Z, Katzir 0, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem. Behar/. 60(2), 387–393 (1998).
   Google Scholar
• Speiser Z, Levy R, Cohen S. Effects of N- propargy1-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. Neural. 7iansm. 52, S287—S300 (1998).
   Google Scholar
• Carrillo MC, Minami C, Kitani K eta]. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67(5), 577–585 (2000).
   PubMed Web of Science ®Google Scholar
• Kim KS, Miller DL, SapienzaV eta]. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neumsci. Res. Corn. 2,121–130 (1988).
   Google Scholar
• Nunan J, Small DH. Regulation of APP cleavage by a-, 0- and y-secretases. FEBS Lett. 483,6–10 (2000).
   PubMed Web of Science ®Google Scholar
• Scheuner D, Eckman C, Jensen M eta! Secreted amyloid 0-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Merl 2,864–870 (1996).
   Google Scholar
• Hung AY, Haass C, Nitsch RM eta! Activation of protein kinase C inhibits cellular production of the amyloid protein. j Biol. Chern. 268,22959–22962 (1993).
   PubMed Web of Science ®Google Scholar
• PERRY G etal The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16,339–352 (2002).
   PubMed Web of Science ®Google Scholar
• Savage MJ, Trusko SP, Howland DS eta]. Turnover of amyloid 0-protein in mouse brain and acute reduction of its level by phorbol ester. Neurosci. 18,1743-1752 (1998).
   Google Scholar
• Checler E Processing of the 0-amyloid precursor protein and its regulation in Alzheimer's disease. j Neurochem. 65, 1431–1444 (1995).
   PubMed Web of Science ®Google Scholar
• Giacobini E, F Mori, Lai CC. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann NY Acad. Sci. 777,393–398 (1996).
   Google Scholar
• Pakaski M, Rakonczay Z, Kasa P. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int. 38,219–226 (2001).
   Google Scholar
• Nitsch RM eta]. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (5080), 304–307 (1992).
   PubMed Web of Science ®Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12,307–323 (1999).
   Web of Science ®Google Scholar
• Weinstock M, Bejar C, Wang RII eta! TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. j Neural. 7iansm. 60, S157-5169 (2000).
   Google Scholar
• Yogev-Falach M, Amit T, Bar-Am 0, SagiY, Weinstock M, Youdim MBH. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. EASE a J. 16,1674-1676 (2002).
   Google Scholar
• Maruyama W Weinstock M, Youdim MB, Nagai M, Naoi M. Anti-apoptotic action of antiAlzheimer drug, TV3326 [(N- propargy1)-(3R)-aminoindan-5-yll -ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett. 341,233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Bar Am 0, Yogev-Falch M, Amit T, Sagi Y, Youdim MBH. Regulation of amyloid precursor protein and protein kinase C functional machinery by the antiparkinson drug, rasagiline and its derivatives, in vivo. Neurochem. (2003) (In Press).
   Google Scholar
• Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9 (4), 703–707 (1998).
   PubMed Web of Science ®Google Scholar
• Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HE The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport11(18), 3937–3941 (2000).
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Amit T, Yogev-Falach M, Bar-Am 0, Maruyama W, Naoi M. The essentiallity of Bc1-2, PKC and proteasome-ubiquitin complex activations in the neuroprotecitve-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol 78,265–268 (2003).
   Google Scholar
• Moruyouna M, Mitta A, Shamoto-Magai M eta! N-Proparyl-1R aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma 5H-SYSY cells through activation of NFkB transcription factor. Neurochem. Internal. (2003) (In Press).
   Google Scholar
• Ravina BM, Fagan SC, Hart RG eta! Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology60, 1234–1240 (2003).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH. Prevention of MPTP neurotoxicity by AGN1133 and AGN-1135, selective inhibitors of monoamine oxidase B. Eur. Pharmacol 116,313–317 (1985).
   Google Scholar